244 related articles for article (PubMed ID: 34224371)
81. Triple-negative breast cancer: immune modulation as the new treatment paradigm.
Disis ML; Stanton SE
Am Soc Clin Oncol Educ Book; 2015; ():e25-30. PubMed ID: 25993181
[TBL] [Abstract][Full Text] [Related]
82. Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.
He TF; Yost SE; Frankel PH; Dagis A; Cao Y; Wang R; Rosario A; Tu TY; Solomon S; Schmolze D; Mortimer J; Lee P; Yuan Y
PLoS One; 2020; 15(3):e0229955. PubMed ID: 32150594
[TBL] [Abstract][Full Text] [Related]
83. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
84. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
[TBL] [Abstract][Full Text] [Related]
85. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
86. Laboratory, morphologic, and immunophenotypic correlates of surface immunoglobulin heavy chain isotype expression in B-cell chronic lymphocytic leukemia.
Shen PU; Fuller SG; Rezuke WN; Sherburne BJ; DiGiuseppe JA
Am J Clin Pathol; 2001 Dec; 116(6):905-12. PubMed ID: 11764081
[TBL] [Abstract][Full Text] [Related]
87. AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression.
Qiao Y; He H; Jonsson P; Sinha I; Zhao C; Dahlman-Wright K
J Biol Chem; 2016 Mar; 291(10):5068-79. PubMed ID: 26792858
[TBL] [Abstract][Full Text] [Related]
88. Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants.
Weller S; Mamani-Matsuda M; Picard C; Cordier C; Lecoeuche D; Gauthier F; Weill JC; Reynaud CA
J Exp Med; 2008 Jun; 205(6):1331-42. PubMed ID: 18519648
[TBL] [Abstract][Full Text] [Related]
89. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells.
Ranheim EA; Cantwell MJ; Kipps TJ
Blood; 1995 Jun; 85(12):3556-65. PubMed ID: 7540066
[TBL] [Abstract][Full Text] [Related]
90. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells.
Klein U; Rajewsky K; Küppers R
J Exp Med; 1998 Nov; 188(9):1679-89. PubMed ID: 9802980
[TBL] [Abstract][Full Text] [Related]
91. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
92. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
93. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
[TBL] [Abstract][Full Text] [Related]
94. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
Schmidt M; Weyer-Elberich V; Hengstler JG; Heimes AS; Almstedt K; Gerhold-Ay A; Lebrecht A; Battista MJ; Hasenburg A; Sahin U; Kalogeras KT; Kellokumpu-Lehtinen PL; Fountzilas G; Wirtz RM; Joensuu H
Breast Cancer Res; 2018 Feb; 20(1):15. PubMed ID: 29482642
[TBL] [Abstract][Full Text] [Related]
95. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer.
Coronella JA; Telleman P; Kingsbury GA; Truong TD; Hays S; Junghans RP
Cancer Res; 2001 Nov; 61(21):7889-99. PubMed ID: 11691809
[TBL] [Abstract][Full Text] [Related]
96. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
97. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
98. Molecular analysis of IgD-positive human germinal centres.
Müller C; Siemer D; Lehnerdt G; Lang S; Küppers R
Int Immunol; 2010 Apr; 22(4):289-98. PubMed ID: 20139173
[TBL] [Abstract][Full Text] [Related]
99. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
Front Immunol; 2020; 11():560074. PubMed ID: 33304345
[TBL] [Abstract][Full Text] [Related]
100. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY; Li Y; Snyder T; Yu T; Lu T; Tzankov A; Visco C; Bhagat G; Qian W; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Wang Y; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Fan X; van Krieken JH; Piris MA; Winter JN; Au Q; Kirsch I; Zhang M; Shaughnessy J; Xu B; Young KH
Clin Cancer Res; 2023 Dec; 29(23):4808-4821. PubMed ID: 37728879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
